Lifesci Capital Downgrades Calliditas Therapeutics AB (publ) (NASDAQ:CALT) to Hold

Lifesci Capital cut shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALTFree Report) from a strong-buy rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports.

A number of other analysts have also recently commented on CALT. HC Wainwright reaffirmed a neutral rating and set a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday. Stifel Nicolaus restated a hold rating and issued a $40.00 price target (down previously from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday. Finally, Jefferies Financial Group reiterated a hold rating and set a $39.00 price objective (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday. Five analysts have rated the stock with a hold rating, According to MarketBeat.com, Calliditas Therapeutics AB (publ) currently has a consensus rating of Hold and an average price target of $34.00.

View Our Latest Analysis on Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ) Stock Up 1.4 %

Calliditas Therapeutics AB (publ) stock opened at $38.47 on Tuesday. The company has a debt-to-equity ratio of 8.46, a current ratio of 2.69 and a quick ratio of 2.62. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -20.80 and a beta of 1.50. Calliditas Therapeutics AB has a 1-year low of $15.25 and a 1-year high of $39.10. The business has a fifty day moving average price of $21.61 and a 200-day moving average price of $21.65.

Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Free Report) last issued its quarterly earnings results on Thursday, May 23rd. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74). Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. The firm had revenue of $28.43 million for the quarter, compared to analyst estimates of $35.78 million. Equities research analysts forecast that Calliditas Therapeutics AB will post -0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. bought a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALTFree Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors own 2.83% of the company’s stock.

About Calliditas Therapeutics AB (publ)

(Get Free Report)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.

Further Reading

Analyst Recommendations for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.